Status:
COMPLETED
To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase Inhibitor in AD Patients.
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
50-90 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to find out if atovastatin, when taken with a cholinesterase inhibitor, is effective for treating Alzheimer's disease.
Eligibility Criteria
Inclusion
- Diagnostic evidence of probable Alzheimer's disease consistent with NINCDS/ADRDA and DSM IV criteria.
- Subject's Mini-Mental Status Examination Score (MMSE) must be in the range of 13 - 25 (inclusive) at Screening.
Exclusion
- Subjects with dementia due to causes other than Alzheimer's disease.
- Any condition, which, in the investigator's judgment might increase the risk to the subject or decrease the reliability of the data required to meet the objectives of the study.
Key Trial Info
Start Date :
November 1 2002
Trial Type :
INTERVENTIONAL
End Date :
July 1 2007
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT00151502
Start Date
November 1 2002
End Date
July 1 2007
Last Update
February 18 2021
Active Locations (99)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Sun City, Arizona, United States, 85351
2
Pfizer Investigational Site
Fresno, California, United States, 93720
3
Pfizer Investigational Site
Laguna Hills, California, United States, 92653
4
Pfizer Investigational Site
San Francisco, California, United States, 94109